Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Szczylik, C., . . . Fizazi, K. (2025). Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: Final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The lancet, 406(10502), . https://doi.org/10.1016/S0140-6736(25)00684-1
Chicago-Zitierstil (17. Ausg.)Agarwal, Neeraj, et al. "Talazoparib Plus Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Results from the Randomised, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet 406, no. 10502 (2025). https://doi.org/10.1016/S0140-6736(25)00684-1.
MLA-Zitierstil (9. Ausg.)Agarwal, Neeraj, et al. "Talazoparib Plus Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Results from the Randomised, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet, vol. 406, no. 10502, 2025, https://doi.org/10.1016/S0140-6736(25)00684-1.